title: [Internal medicine in the hospital setting].
abstract: Management of all pathologies, and in particular that of the most frequent ones, should whenever possible be based on robust evidence and arguments. New studies published this year enable rationalizing of screening in certain clinical situations, more adequate treatment of others, and open the way for novel and apparently very effective treatments. Whether it be the screening of carotid stenosis, the treatment of pericarditis, of heart failure, of chronic obstructive lung disease or spontaneous bacterial peritonitis, paradigm changes are conceivable. This selective review of the literature summarizes certain studies published this year.
authors.forename: M
authors.initials: M
authors.lastname: Moret
authors.forename: P
authors.initials: P
authors.lastname: Darbellay
authors.forename: D
authors.initials: D
authors.lastname: Lebowitz
authors.forename: C
authors.initials: C
authors.lastname: Alves
authors.forename: N
authors.initials: N
authors.lastname: Sabeh
authors.forename: S
authors.initials: S
authors.lastname: Carballo
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000009:adverse effects; D000613:Aminobutyrates / Q000627:therapeutic use; D057911:Angiotensin Receptor Antagonists / Q000627:therapeutic use; D058070:Asymptomatic Diseases; D001281:Atrial Fibrillation / Q000150:complications; D001713:Biphenyl Compounds; D016893:Carotid Stenosis / Q000175:diagnosis; D003078:Colchicine / Q000627:therapeutic use; D004232:Diuretics / Q000627:therapeutic use; D004338:Drug Combinations; D006333:Heart Failure / Q000188:drug therapy; D006761:Hospitals; D006801:Humans; D007388:Internal Medicine / Q000639:trends*; D008103:Liver Cirrhosis / Q000150:complications; D009294:Narcotics / Q000627:therapeutic use; D015260:Neprilysin / Q000037:antagonists & inhibitors; D010493:Pericarditis / Q000517:prevention & control; D010538:Peritonitis / Q000150:complications; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy / Q000628:therapy; D012138:Respiratory Therapy; D013148:Spironolactone / Q000627:therapeutic use; D020521:Stroke / Q000209:etiology; D013777:Tetrazoles / Q000627:therapeutic use; D000068756:Valsartan
chemical_list: D000319:Adrenergic beta-Antagonists; D000613:Aminobutyrates; D057911:Angiotensin Receptor Antagonists; D001713:Biphenyl Compounds; D004232:Diuretics; D004338:Drug Combinations; D009294:Narcotics; D013777:Tetrazoles; D013148:Spironolactone; D000068756:Valsartan; D015260:Neprilysin; D003078:Colchicine; C549068:sacubitril and valsartan sodium hydrate drug combination